Nasdaq:REPL
Replimune Group, Inc.
A clinical-stage immuno-oncology developer advancing proprietary CAR-NK cell therapies for cancer treatment.
Key Metrics
Investment Thesis
Bull Case
Investors might buy based on the potential for high-impact immuno-oncology breakthroughs if clinical trials succeed, leveraging the company's proprietary technology platform to capture significant market share upon approval. The current lack of commercial revenue represents an optionality value where a single success could generate exponential returns in a lucrative cancer treatment market.
Bear Case
The stock carries extreme risk due to zero revenue, massive accumulated deficits of nearly $1B, and negative cash flows from operations that require continuous dilution or external funding. Investors should avoid the stock if they prioritize financial stability, as the company has no earnings history and faces high uncertainty regarding future clinical outcomes.
About Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies to treat various cancers using engineered immune cells. The company primarily serves oncology markets globally through its proprietary platform of CAR-NK cell therapies designed to target solid and hematologic malignancies.
Analysis
Management Discussion
Management has maintained substantial cash positions with ending cash at $112.8M, yet the company continues to burn approximately $247M annually in net profit terms. The reliance on common share issuances ($155.7M) and financing cash flow ($252.4M) highlights a capital-intensive growth strategy typical of pre-revenue biotechs.
Industry Overview
The immuno-oncology industry is characterized by high failure rates but massive potential rewards, with companies investing billions in R&D to engineer cells that can recognize and destroy tumors. Success depends on navigating complex regulatory pathways and achieving clinical efficacy while managing substantial cash burn until product commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $177.1M | $234.8M | $261.6M |
| Operating Income | $-177.1M | $-234.8M | $-261.6M |
| R&D | $126.5M | $175.0M | $189.4M |
| G&A | $50.6M | $59.8M | $72.2M |
| Stock-Based Comp | $28.1M | $34.1M | $35.0M |
| D&A | $2.4M | $2.7M | $3.5M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $3.1M | $19.4M | $14.8M |
| Pre-Tax Income | $-174.0M | $-215.4M | $-246.8M |
| Income Tax | $288.0K | $408.0K | $468.0K |
| Continuing Ops | $-174.0M | $-215.4M | $-246.8M |
| Discontinued Ops | $-288.0K | $-408.0K | $-468.0K |
| Net Income | $-174.3M | $-215.8M | $-247.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-174.3M | $-215.8M | $-247.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $592.6M | $433.7M | $495.9M |
| Cash & Equivalents | $146.6M | $74.5M | $111.1M |
| Marketable Securities | $436.8M | $346.2M | $372.7M |
| Prepaid Expenses | $6.3M | $8.1M | $8.4M |
| Other Current Assets | $2.9M | $4.9M | $3.7M |
| Long-Term Assets | $54.0M | $54.1M | $55.4M |
| PP&E (Net) | $7.5M | $10.5M | $13.7M |
| Operating Leases | $5.2M | $4.6M | $4.0M |
| Other LT Assets | $41.3M | $38.9M | $37.7M |
| Total Assets | $646.6M | $487.7M | $551.3M |
| Current Liabilities | $33.8M | $40.4M | $62.4M |
| Accounts Payable | $5.4M | $2.6M | $12.5M |
| Current Leases | $1.1M | $1.2M | $1.2M |
| Other Current Liab | $27.3M | $36.7M | $48.7M |
| Long-Term Liabilities | $57.5M | $72.8M | $73.1M |
| Long-Term Debt | $28.6M | $44.8M | $46.4M |
| LT Operating Leases | $4.4M | $3.8M | $3.1M |
| Other LT Liab | $24.4M | $24.2M | $23.7M |
| Total Liabilities | $91.3M | $113.2M | $135.5M |
| Shareholders' Equity | $555.3M | $374.5M | $415.8M |
| Paid-In Capital | $1.03B | $1.07B | $1.36B |
| Retained Earnings | $-485.5M | $-701.3M | $-948.6M |
| AOCI | $5.7M | $4.9M | $5.4M |
| Total L&E | $646.6M | $487.7M | $551.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-174.3M | $-215.8M | $-247.3M |
| Non-Cash Adjustments | $43.0M | $31.6M | $44.2M |
| Working Capital Changes | $3.3M | $-1.3M | $10.8M |
| Cash from Operations | $-128.1M | $-185.5M | $-192.2M |
| Capital Expenditures | $2.3M | — | — |
| Cash from Investing | $-142.5M | $97.2M | $-23.8M |
| Debt Issuances | $28.2M | $15.0M | $0 |
| Cash from Financing | $311.3M | $16.3M | $252.4M |
| FX Effect | $-109.0K | $-86.0K | $315.0K |
| Net Change in Cash | $40.6M | $-72.1M | $36.7M |
| Beginning Cash | $107.6M | $148.2M | $76.2M |
| Ending Cash | $148.2M | $76.2M | $112.8M |
Frequently Asked Questions
How does Replimune Group, Inc. make money?
The company's financials reflect a heavy investment in research and development ($189.4M), indicating a single primary segment focused on drug discovery and clinical trials, with no current commercial revenue streams as cost of revenue is zero.
What are the main risks for REPL?
1. Complete lack of commercial revenue and profitability, relying entirely on capital markets for survival. 2. Significant accumulated losses exceeding $948M indicate a history of financial distress or heavy burn rates. 3. High operating expenses ($261.6M) relative to cash flow from operations (-$192.2M) suggest rapid depletion of liquidity without sales.
What is REPL's competitive advantage?
1. Proprietary CAR-NK platform offering potential manufacturing and scalability advantages over viral vectors. 2. Strategic cash reserves of $111.1M combined with recent financing inflows provide runway for extended clinical development. 3. Diversified asset pipeline targeting multiple cancer indications to mitigate single-failure risk.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.